Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) Given Average Recommendation of “Buy” by Analysts

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has been given an average rating of “Buy” by the six brokerages that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $13.33.

Several equities analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. Needham & Company LLC started coverage on shares of Aeglea Bio Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $11.00 target price on the stock. BidaskClub upgraded shares of Aeglea Bio Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, June 17th. Piper Sandler started coverage on shares of Aeglea Bio Therapeutics in a report on Monday, May 4th. They set an “overweight” rating and a $12.00 price objective on the stock. Finally, HC Wainwright dropped their price objective on shares of Aeglea Bio Therapeutics from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, May 8th.

In other Aeglea Bio Therapeutics news, CEO Anthony G. Quinn bought 165,000 shares of the firm’s stock in a transaction dated Thursday, April 30th. The stock was bought at an average cost of $4.75 per share, with a total value of $783,750.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 13.70% of the stock is currently owned by corporate insiders.

Several large investors have recently bought and sold shares of the company. Citigroup Inc. increased its position in shares of Aeglea Bio Therapeutics by 22.9% during the first quarter. Citigroup Inc. now owns 9,355 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 1,745 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Aeglea Bio Therapeutics by 5.3% during the first quarter. Bank of New York Mellon Corp now owns 95,106 shares of the biotechnology company’s stock worth $443,000 after acquiring an additional 4,763 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in shares of Aeglea Bio Therapeutics by 150.4% during the first quarter. BNP Paribas Arbitrage SA now owns 8,073 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 4,849 shares in the last quarter. Franklin Street Advisors Inc. NC increased its position in shares of Aeglea Bio Therapeutics by 16.7% during the first quarter. Franklin Street Advisors Inc. NC now owns 35,000 shares of the biotechnology company’s stock worth $163,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Aeglea Bio Therapeutics by 414.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,312 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 5,890 shares in the last quarter. 46.09% of the stock is owned by institutional investors.

AGLE stock traded up $0.09 during mid-day trading on Tuesday, hitting $9.25. 253,687 shares of the company were exchanged, compared to its average volume of 185,774. The business has a 50 day simple moving average of $8.78 and a 200-day simple moving average of $7.26. The company has a current ratio of 3.17, a quick ratio of 3.17 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $410.70 million, a PE ratio of -3.81 and a beta of 2.08. Aeglea Bio Therapeutics has a 1-year low of $3.50 and a 1-year high of $11.38.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.08. Equities research analysts expect that Aeglea Bio Therapeutics will post -1.71 earnings per share for the current year.

About Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Read More: What is the operating income formula?

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.